Abstract
Kirsten rat sarcoma viral oncogene (K-ras) is one of the most frequent mutations of non-small cell lung cancer (NSCLC), specifically lung adenocarcinoma. Historically K-ras has been a mutation of great resilience and complexity. This shifted the focus of therapies to several of its related signaling pathways and cytokines. However, due to a greater understanding of the intricacies behind this mutation a greater arsenal of therapies has become available to us in the form of direct K-ras therapy. With this cumulative knowledge, we hope to bring an end to this irrepressible mutation in the future.
Original language | English (US) |
---|---|
Title of host publication | Encyclopedia of Respiratory Medicine, Second Edition |
Publisher | Elsevier |
Pages | 876-888 |
Number of pages | 13 |
Volume | 5 |
ISBN (Electronic) | 9780081027240 |
ISBN (Print) | 9780081027233 |
DOIs | |
State | Published - Jan 1 2021 |
Keywords
- Cytokine
- Immunotherapy
- K-ras
- Lung cancer
- Signaling pathway
ASJC Scopus subject areas
- General Medicine